Publikation
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.
Wissenschaftlicher Artikel/Review - 25.07.2024
Fleischmann Roy, Meerwein Sebastian, Charles-Schoeman Christina, Combe Bernard, Hall Stephen, Khan Nasser, Carter Kyle M, Camp Heidi S, Rubbert-Roth Andrea
Bereiche
PubMed
DOI
Kontakt
Zitation
Fleischmann R, Meerwein S, Charles-Schoeman C, Combe B, Hall S, Khan N, Carter K, Camp H, Rubbert-Roth A. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD Open 2024; 10
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
RMD Open 2024; 10
Veröffentlichungsdatum
25.07.2024
eISSN (Online)
2056-5933
Kurzbeschreibung/Zielsetzung
To evaluate the efficacy and safety of upadacitinib over 5 years among patients with rheumatoid arthritis (RA) in a long-term extension (LTE) of the SELECT-BEYOND phase 3 trial.